Phase 2 Obesity Trial, Recruiting NCT07395960 Sponsor: Fudan University Condition: Obesity
Back to Obesity

Phase 2 Obesity Trial, Recruiting

NCT07395960
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 60 and 75 years old
  • People with a body mass index (a measure of body weight relative to height) of 24 or higher
  • People whose recent blood sugar control test (called glycated hemoglobin, or HbA1c) shows a result below 8.5%
  • People whose score on a memory and thinking assessment (called the MoCA scale) falls between 20 and 26 points (for those with more than 10 years of education) or between 20 and 25 points (for those with 10 years of education or fewer)
  • People who are willing to sign a consent form agreeing to take part in the trial

Who may not be able to join:

  • People who have used any blood sugar-lowering medications in the 8 weeks before enrolling
  • People who have Type 1 diabetes
  • People who are unable to have a brain MRI scan (a type of detailed imaging of the brain)
  • People with a history of alcohol or drug addiction
  • People with serious digestive system conditions, a history of stomach or bowel surgery, serious heart or lung problems, or cancer
  • People with abnormal liver function (where certain liver-related markers in blood tests are more than 2.5 times higher than the normal upper limit) or reduced kidney function (confirm with trial site for specific measurement details)
  • People who have conditions such as stroke-related brain damage or vascular dementia
  • People whom the trial doctors judge to be unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xiaoming Tao, Huadong Hospital

Phone: +8613042190822

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

fMRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov